- Chardan’s Inaugural Microbiome Summit: a corporate overview will be presented on Thursday, March 7th at 8:10 a.m. ET in New York, NY.
- Cowen and Company 39th Annual Health Care Conference: a corporate overview will be presented on Monday, March 11th at 11:20 a.m. ET in Boston, MA.
- Oppenheimer 29th Annual Healthcare Conference: a corporate overview will be presented on Tuesday, March 19th at 11:30 a.m. ET in New York, NY.
A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay will become available approximately one hour after each event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ most advanced program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for recurrent C. difficile infection. SER-287 is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. For more information, please visit www.serestherapeutics.com.